A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma
Clinical trial NCT02967692 · TERMINATED
Trial details
- NCT number
- NCT02967692
- Sponsor
- Novartis Pharmaceuticals
- Status
- TERMINATED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2017-02-17
- Primary completion
- 2020-08-11
- Enrollment
- 568
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.